Allergy Therapeutics suffers phase 3 birch allergy jab trial failureUK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest Share XAllergy Therapeutics suffers phase 3 birch allergy jab trial failurehttps://pharmaphorum.com/news/allergy-therapeutics-suffers-phase-3-birch-allergy-jab-trial-failure/
Karuna raises $68m to develop neurology drug KarXTKaruna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 Share XKaruna raises $68m to develop neurology drug KarXThttps://pharmaphorum.com/news/karuna-raises-68m-to-develop-neurology-drug-karxt/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Imara raises $63m for sickle cell drug trialsUS biotech Imara has raised $63 million for clinical development of its sickle cell disease drug, which is Share XImara raises $63m for sickle cell drug trialshttps://pharmaphorum.com/news/imara-raises-63m-for-sickle-cell-drug-trials/
Apple Watch shows early promise in AFib diagnosisA large-scale study has provided some evidence that the Apple Watch could be used to detect atrial fibrillation Share XApple Watch shows early promise in AFib diagnosishttps://pharmaphorum.com/news/apple-watch-shows-early-promise-in-afib-diagnosis/
Merck KGaA signs another AI dealMerck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative Share XMerck KGaA signs another AI dealhttps://pharmaphorum.com/news/merck-kgaa-signs-another-ai-deal/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Study will gauge impact of smartphone on memory and focusScientists are to use an app to conduct the first crowdsourcing study on the impact of smartphone use Share XStudy will gauge impact of smartphone on memory and focushttps://pharmaphorum.com/news/study-will-gauge-impact-of-smartphone-on-memory-and-focus/
EU expands use of Roche’s new haemophilia A drugThe European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the Share XEU expands use of Roche’s new haemophilia A drughttps://pharmaphorum.com/news/eu-expands-use-of-roches-new-haemophilia-a-drug/
